BR0315657A - Formulação de dosagem sólida, comprimido para liberação controlada, método de fabricar uma medicação de liberação controlada, composição farmacêutica e uso de uma composição - Google Patents

Formulação de dosagem sólida, comprimido para liberação controlada, método de fabricar uma medicação de liberação controlada, composição farmacêutica e uso de uma composição

Info

Publication number
BR0315657A
BR0315657A BR0315657-5A BR0315657A BR0315657A BR 0315657 A BR0315657 A BR 0315657A BR 0315657 A BR0315657 A BR 0315657A BR 0315657 A BR0315657 A BR 0315657A
Authority
BR
Brazil
Prior art keywords
controlled release
composition
solid dosage
dosage formulation
manufacturing
Prior art date
Application number
BR0315657-5A
Other languages
English (en)
Inventor
Vincent Lenaerts
Jonathan Bacon
Rachid Ouzerourou
Sonia Gervais
Miloud Rahmouni
Damon Smith
Laure Patricia Quadji-Njiki
Original Assignee
Labopharm Inc
Labopharm Europe Ltd
Labopharm Barbados Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Labopharm Inc, Labopharm Europe Ltd, Labopharm Barbados Ltd filed Critical Labopharm Inc
Publication of BR0315657A publication Critical patent/BR0315657A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin

Abstract

"FORMULAçãO DE DOSAGEM SóLIDA, COMPRIMIDO PARA LIBERAçãO CONTROLADA, MéTODO DE FABRICAR UMA MEDICAçãO DE LIBERAçãO CONTROLADA, COMPOSIçãO FARMACêUTICA E USO DE UMA COMPOSIçãO". Formulação de dosagem sólida tendo um núcleo com um agente farmacológico dispersado em uma primeira matriz de liberação controlada, a partir da qual a liberação do agente é relativamente lenta; e um revestimento formado sobre o núcleo e tendo o agente dispersado em uma segunda matriz de liberação controlada, a partir da qual a liberação do agente é relativamente rápida. A primeira matriz pode ser um amido de alto teor de amilose reticulado e a segunda matriz pode ser uma mistura de acetato de polivinila e polivinil pirrolidona.
BR0315657-5A 2002-10-25 2003-10-27 Formulação de dosagem sólida, comprimido para liberação controlada, método de fabricar uma medicação de liberação controlada, composição farmacêutica e uso de uma composição BR0315657A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50906202P 2002-10-25 2002-10-25
US28102602A 2002-10-25 2002-10-25
PCT/CA2003/001637 WO2004038428A2 (en) 2002-10-25 2003-10-27 Controlled-release compositions

Publications (1)

Publication Number Publication Date
BR0315657A true BR0315657A (pt) 2005-09-13

Family

ID=34976756

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0315657-5A BR0315657A (pt) 2002-10-25 2003-10-27 Formulação de dosagem sólida, comprimido para liberação controlada, método de fabricar uma medicação de liberação controlada, composição farmacêutica e uso de uma composição

Country Status (19)

Country Link
EP (1) EP1558935B1 (pt)
JP (1) JP2006507276A (pt)
KR (1) KR101120729B1 (pt)
AT (1) ATE400819T1 (pt)
AU (1) AU2003275854B9 (pt)
BR (1) BR0315657A (pt)
CA (1) CA2503361C (pt)
DE (1) DE60322091D1 (pt)
DK (1) DK1558935T3 (pt)
EC (1) ECSP055748A (pt)
ES (1) ES2310686T3 (pt)
HK (1) HK1086475A1 (pt)
MX (1) MXPA05004410A (pt)
NO (1) NO20052515L (pt)
NZ (1) NZ539869A (pt)
PT (1) PT1558935E (pt)
RU (1) RU2333745C2 (pt)
SI (1) SI1558935T1 (pt)
WO (1) WO2004038428A2 (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8487002B2 (en) 2002-10-25 2013-07-16 Paladin Labs Inc. Controlled-release compositions
TWI319713B (en) 2002-10-25 2010-01-21 Sustained-release tramadol formulations with 24-hour efficacy
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
JP2005306778A (ja) * 2004-04-21 2005-11-04 Basf Ag 徐放性製剤及びその製造方法
WO2006009602A2 (en) 2004-06-16 2006-01-26 Tap Pharmaceutical Products, Inc. Multiple ppi dosage form
CA2491665A1 (fr) * 2004-12-24 2006-06-24 Louis Cartilier Formulation de comprime pour liberation soutenue de principe actif
KR20080039400A (ko) 2005-07-07 2008-05-07 파남 컴퍼니스 인크. 고수용성 약물의 서방성 약학 조성물
BRPI0615860B8 (pt) * 2005-09-09 2021-05-25 Labopharm Barbados Ltd composição farmacêutica de liberação prolongada monolítica sólida
CN100437113C (zh) * 2006-04-11 2008-11-26 汪运山 一种检测血液中非那西丁与醋氨酚浓度比值的试剂盒
EP2010158B1 (en) 2006-04-26 2016-02-17 Alphapharm Pty Ltd. Controlled release formulations comprising uncoated discrete unit(s) and an extended release matrix
AU2013202441B2 (en) * 2006-04-26 2016-02-25 Alphapharm Pty Ltd Controlled release formulations comprising uncoated discrete unit(s) and an extended release matrix
CN100387988C (zh) * 2006-07-25 2008-05-14 山东省医药工业研究所 一种布洛伪麻那敏复方制剂的含量检测方法
PT2120878E (pt) 2007-02-09 2014-11-05 Alphapharm Pty Ltd Forma farmacêutica contendo duas ou mais substancias ativas em diferentes formas físicas
KR20100069685A (ko) 2007-10-16 2010-06-24 라보팜 인코포레이트 아세트아미노펜과 트라마돌의 지속 방출을 위한 이중층 조성물
ES2419204T3 (es) 2008-05-27 2013-08-19 The University Of Melbourne Métodos para tratar a mamíferos con disfunciones de la trompa de Eustaquio
DK3045043T3 (da) 2009-02-26 2020-08-03 Relmada Therapeutics Inc Orale farmaceutiske sammensætninger af 3-hydroxy-n-methylmorphinan med forlænget frigivelse og fremgangsmåde til anvendelse
CA2775890C (en) 2009-09-30 2016-06-21 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse
US20130039864A1 (en) * 2010-04-23 2013-02-14 Francois Ravenelle Non-Intravenous Dosage Form Comprising Solid Formulation of Liquid Biologically Active Agent and Uses Thereof
RU2451680C1 (ru) 2011-02-21 2012-05-27 Общество С Ограниченной Ответственностью "Научно-Исследовательская Компания "Медбиофарм" Клатратный комплекс циклодекстрина или арабиногалактана с 9-фенил-симм-октагидроселеноксантеном, способ его получения (варианты), фармацевтическая композиция и лекарственное средство
CN107595793B (zh) 2012-11-30 2020-11-13 阿库拉制药公司 活性药物成分的自调节释放
WO2017040607A1 (en) 2015-08-31 2017-03-09 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient
CN114177155B (zh) * 2020-09-08 2023-10-03 越洋医药开发(广州)有限公司 一种布洛芬控释片及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ260408A (en) * 1993-05-10 1996-05-28 Euro Celtique Sa Controlled release preparation comprising tramadol
DE19530575A1 (de) * 1995-08-19 1997-02-20 Gruenenthal Gmbh Schnell zerfallende Arzneiform von Tramadol oder einem Tramadolsalz
CA2173818A1 (fr) * 1996-04-10 1997-10-11 Francois Chouinard Comprime pharmaceutique a liberation controlee contenant un support a base d'amylose reticule et d'hydroxypropylmethylcellulose
WO1999001111A1 (en) * 1997-07-02 1999-01-14 Euro-Celtique, S.A. Stabilized sustained release tramadol formulations
US6284273B1 (en) * 1998-02-24 2001-09-04 Vincent Lenaerts Cross-linked high amylose starch resistant to amylase as a matrix for the slow release of biologically active compounds
DE10014588A1 (de) * 2000-03-27 2001-10-04 Basf Ag Wirkstoffhaltige Schwimmformen enthaltend Polyvinylacetat und Polyvinylpyrrolidon, deren Verwendung und Herstellung
DE10015479A1 (de) * 2000-03-29 2001-10-11 Basf Ag Feste orale Darreichungsformen mit retardierter Wirkstofffreisetzung und hoher mechanischer Stabilität
US6607748B1 (en) * 2000-06-29 2003-08-19 Vincent Lenaerts Cross-linked high amylose starch for use in controlled-release pharmaceutical formulations and processes for its manufacture
JP5502254B2 (ja) * 2001-01-31 2014-05-28 エボニック レーム ゲゼルシャフト ミット ベシュレンクテル ハフツング 少なくとも２種類の異なる被覆ペレット形から成る多粒子剤形

Also Published As

Publication number Publication date
EP1558935A2 (en) 2005-08-03
HK1086475A1 (en) 2006-09-22
SI1558935T1 (sl) 2008-12-31
KR101120729B1 (ko) 2012-04-23
AU2003275854A1 (en) 2004-05-13
JP2006507276A (ja) 2006-03-02
DE60322091D1 (de) 2008-08-21
EP1558935B1 (en) 2008-07-09
CA2503361A1 (en) 2004-05-06
NO20052515D0 (no) 2005-05-25
NO20052515L (no) 2005-05-25
KR20050088281A (ko) 2005-09-05
AU2003275854B9 (en) 2009-08-27
ATE400819T1 (de) 2008-07-15
PT1558935E (pt) 2008-10-16
AU2003275854B2 (en) 2008-09-11
DK1558935T3 (da) 2008-11-17
WO2004038428A3 (en) 2005-06-09
MXPA05004410A (es) 2005-11-23
WO2004038428A2 (en) 2004-05-06
ES2310686T3 (es) 2009-01-16
RU2333745C2 (ru) 2008-09-20
RU2005115883A (ru) 2006-01-27
NZ539869A (en) 2007-09-28
CA2503361C (en) 2012-02-28
ECSP055748A (es) 2005-08-11

Similar Documents

Publication Publication Date Title
BR0315657A (pt) Formulação de dosagem sólida, comprimido para liberação controlada, método de fabricar uma medicação de liberação controlada, composição farmacêutica e uso de uma composição
NL2000281A1 (nl) Vaste farmaceutische samenstellingen die pregabaline bevatten.
WO2004064815A8 (en) Oral dosage formulation
ATE512659T1 (de) Tablette mit verzögerter wirkstofffreigabe und bestimmter formgeometrie
PT1166776E (pt) Processo para a preparacao de formas de apresentacao farmaceutica orais solidas com libertacao retardada da substancia activa
EA200700201A1 (ru) Композиция таблетки пролонгированного высвобождения, содержащая прамипексол или его фармацевтически приемлемую соль, способ ее изготовления и ее применение
CL2009000541A1 (es) Uso de una enzima degradadora de matriz activable (amde) para la formulacion de un medicamento de administracion sub-epidermica; composicion farmacologica y su uso; combinacion que comprende a amde, un activador y un agente; recipiente para amde y para el activador; kit que comprende dicho recipiente
HRP20100372T1 (hr) Farmaceutski sastavi neuroaktivnog steroida i njihova uporaba
NO20084065L (no) Hurtig frigivelses paracetamol tabletter
MX9707585A (es) Mezclas homogeneas de farmacos y aditivos de fusion a baja temperatura para liberacion controlada.
WO2007025182A3 (en) Drug compositions containing controlled release hypromellose matrices
TR201819108T4 (tr) Kontrollü salımlı matrisli farmasötik dozaj formülasyonu.
WO2007143163A3 (en) Pharmaceutical compositions for sustained release of phenyephrine
ATE185266T1 (de) Schnell auflösende orale darreichungsform
ATE479428T1 (de) Olanzapin enthaltende pharmazeutische zusammensetzung
MY142195A (en) Controlled-release compositions
UA86929C2 (ru) Композиция с контролируемым высвобождением
BRPI0315657B8 (pt) formulação de dosagem sólida, comprimido para liberação controlada, método de fabricar uma medicação de liberação controlada, composição farmacêutica e uso de uma composição
PT1499278E (pt) Forma de dosagem farmaceutica de libertacao imediata compreendendo tibolona polimorfa
WO2008038155A3 (en) Controlled-release pharmaceutical tablets
KR20100133757A (ko) 염산 알푸조신 함유 서방성 정제

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: A CLASSIFICACAO ANTERIOR ERA: A61K 9/20

Ipc: A61K 9/20 (2006.01), A61K 9/22 (2006.01), A61K 9/2

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B25A Requested transfer of rights approved

Owner name: LABOPHARM EUROPE LIMITED (IE) , LABOPHARM (BARBADO

B25D Requested change of name of applicant approved

Owner name: LABOPHARM EUROPE LIMITED (IE) , LABOPHARM (BARBADO

B25A Requested transfer of rights approved

Owner name: LABOPHARM EUROPE LIMITED (IE) , LABOPHARM (BARBADO

B25D Requested change of name of applicant approved

Owner name: LABOPHARM (BARBADOS) LIMITED (BB) , PALADIN LABS I

B25G Requested change of headquarter approved

Owner name: PALADIN LABS INC. (CA) , PALADIN LABS EUROPE LIMIT

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8, 13 E 25 DA LPI

B25A Requested transfer of rights approved

Owner name: PALADIN LABS INC. (CA) , PALADIN LABS EUROPE LIMIT

B25D Requested change of name of applicant approved

Owner name: PALADIN LABS INC. (CA) , PALADIN LABS EUROPE LIMIT

B12B Appeal against refusal [chapter 12.2 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 11/09/2018, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/10/2003 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF